Brain Metastasis - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 174 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Brain Metastasis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Brain Metastasis - Pipeline Review, H1 2015', provides an overview of the Brain Metastasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Metastasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Brain Metastasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Brain Metastasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Brain Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Brain Metastasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Brain Metastasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Brain Metastasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Brain Metastasis Overview 10
Therapeutics Development 11
Pipeline Products for Brain Metastasis - Overview 11
Pipeline Products for Brain Metastasis - Comparative Analysis 12
Brain Metastasis - Therapeutics under Development by Companies 13
Brain Metastasis - Therapeutics under Investigation by Universities/Institutes 15
Brain Metastasis - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Brain Metastasis - Products under Development by Companies 18
Brain Metastasis - Products under Investigation by Universities/Institutes 20
Brain Metastasis - Companies Involved in Therapeutics Development 21
AbbVie Inc. 21
AngioChem Inc. 22
BBB Therapeutics B.V. 23
biOasis Technologies Inc. 24
Bristol-Myers Squibb Company 25
Diffusion Pharmaceuticals LLC 26
e-Therapeutics plc 27
Exelixis, Inc. 28
GlaxoSmithKline plc 29
Hutchison MediPharma Limited 30
Komipharm International Co., Ltd. 31
Nanobiotix 32
Nektar Therapeutics 33
Nerviano Medical Sciences S.r.l. 34
Novartis AG 35
Pfizer Inc. 36
Philogen S.p.A. 37
Phosplatin Therapeutics LLC 38
Puma Biotechnology, Inc. 39
Radius Health, Inc. 40
Sanofi 41
Spectrum Pharmaceuticals, Inc. 42
Tocagen Inc. 43
Brain Metastasis - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Combination Products 45
Assessment by Target 46
Assessment by Mechanism of Action 49
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
2B3-101 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ANG-1005 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ANG-4043 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
BT-2111 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
cabazitaxel - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
cabozantinib s-malate - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
dabrafenib mesylate - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
dacomitinib - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Drug for Brain Metastasis - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
etirinotecan pegol - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
ETS-2101 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Gene Therapy to Activate p53 for Oncology - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
HMPL-813 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
ipilimumab - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
KML-001 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
lapatinib ditosylate - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
lucanthone hydrochloride - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
NBTX-IV - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
neratinib - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
nimotuzumab - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
NMSE-973 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
PB-357 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
PT-112 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
RAD-1901 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
radretumab - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
RRX-001 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
transcrocetinate sodium - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
veliparib - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
vocimagene amiretrorepvec + flucytosine ER - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Brain Metastasis - Recent Pipeline Updates 115
Brain Metastasis - Dormant Projects 163
Brain Metastasis - Discontinued Products 164
Brain Metastasis - Product Development Milestones 165
Featured News & Press Releases 165
Aug 28, 2014: Radius Health Reports Proof of Mechanism for RAD1901 and Presentation at 4th Annual Brain Metastases Research and Emerging Therapy Conference in September 165
Nov 12, 2013: Study Demonstrates biOasis Technologies' Conjugate of Metastatic Cancer Drug, Herceptin, Penetrates Blood-Tumor Barrier 10 Times Greater Than Herceptin Alone 166
Oct 08, 2013: Angiochem to Present at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 167
Aug 19, 2013: to-BBB Receives IND Approval for Novel Brain Cancer Drug, 2B3-101 167
Jul 29, 2013: Nerviano Medical Sciences researchers report data on a novel molecule inhibitor of HSP90 168
Jun 26, 2013: Nanobiotix Announces Selection Of Its Second NanoXray Product NBTX-IV And Collaboration With National Cancer Institute For Development 168
Apr 09, 2013: biOasis Provides Update On BT2111-Herceptin Program 169
Dec 03, 2012: Geron Discontinues Development Of Brain Cancer Drug Candidate GRN1005 169
Dec 22, 2011: Geron Initiates Phase II Trial Of GRN1005 In Brain Metastases Arising From Lung Cancer 169
Nov 15, 2011: Geron Presents Final Phase I Clinical Data On GRN1005 At AACR-NCI-EORTC 170
Appendix 173
Methodology 173
Coverage 173
Secondary Research 173
Primary Research 173
Expert Panel Validation 173
Contact Us 173
Disclaimer 174

List of Tables

Number of Products under Development for Brain Metastasis, H1 2015 11
Number of Products under Development for Brain Metastasis - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2015 20
Brain Metastasis - Pipeline by AbbVie Inc., H1 2015 21
Brain Metastasis - Pipeline by AngioChem Inc., H1 2015 22
Brain Metastasis - Pipeline by BBB Therapeutics B.V., H1 2015 23
Brain Metastasis - Pipeline by biOasis Technologies Inc., H1 2015 24
Brain Metastasis - Pipeline by Bristol-Myers Squibb Company, H1 2015 25
Brain Metastasis - Pipeline by Diffusion Pharmaceuticals LLC, H1 2015 26
Brain Metastasis - Pipeline by e-Therapeutics plc, H1 2015 27
Brain Metastasis - Pipeline by Exelixis, Inc., H1 2015 28
Brain Metastasis - Pipeline by GlaxoSmithKline plc, H1 2015 29
Brain Metastasis - Pipeline by Hutchison MediPharma Limited, H1 2015 30
Brain Metastasis - Pipeline by Komipharm International Co., Ltd., H1 2015 31
Brain Metastasis - Pipeline by Nanobiotix, H1 2015 32
Brain Metastasis - Pipeline by Nektar Therapeutics, H1 2015 33
Brain Metastasis - Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 34
Brain Metastasis - Pipeline by Novartis AG, H1 2015 35
Brain Metastasis - Pipeline by Pfizer Inc., H1 2015 36
Brain Metastasis - Pipeline by Philogen S.p.A., H1 2015 37
Brain Metastasis - Pipeline by Phosplatin Therapeutics LLC, H1 2015 38
Brain Metastasis - Pipeline by Puma Biotechnology, Inc., H1 2015 39
Brain Metastasis - Pipeline by Radius Health, Inc., H1 2015 40
Brain Metastasis - Pipeline by Sanofi, H1 2015 41
Brain Metastasis - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 42
Brain Metastasis - Pipeline by Tocagen Inc., H1 2015 43
Assessment by Monotherapy Products, H1 2015 44
Assessment by Combination Products, H1 2015 45
Number of Products by Stage and Target, H1 2015 47
Number of Products by Stage and Mechanism of Action, H1 2015 50
Number of Products by Stage and Route of Administration, H1 2015 52
Number of Products by Stage and Molecule Type, H1 2015 54
Brain Metastasis Therapeutics - Recent Pipeline Updates, H1 2015 115
Brain Metastasis - Dormant Projects, H1 2015 163
Brain Metastasis - Discontinued Products, H1 2015 164